ZonMw: The Netherlands Organisation for Health Research and Development

Start date

January 2011

End date

October 2013

Trial size

380 participants

Trial identifier

NCT01217307, GIPS-III 2010B257

Summary

The investigators will evaluate the effect of metformin therapy during 4 months in
non-diabetic patients following ST-elevation myocardial infarction on left ventricular
ejection fraction as measured with cardiac magnetic resonance imaging, compared to placebo.

In this trial, the investigators will evaluate the effect of metformin therapy following
ST-elevation myocardial infarction (STEMI) in a total of 380 non-diabetic patients. This
trial is a randomized, double blind, controlled trial. The intervention, which consist of
metformin 500mg twice daily or placebo twice daily, will commence within three hours after
the percutaneous coronary intervention, and will be continued for 4 months. The primary
endpoint is the difference between the two intervention groups (metformin vs placebo) in
left ventricular ejection fraction, as measured with magnetic resonance imaging after 4
months. The investigators hypothesize that metformin therapy results in a significantly
higher ejection fraction in this population.

Trial information was received from ClinicalTrials.gov and was last updated in October 2013.

Information provided to ClinicalTrials.gov by University Medical Centre Groningen.